• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Xeris Pharmaceuticals touts data for glucagon auto-injector

November 14, 2018 By Sarah Faulkner

Xeris Pharmaceuticals logo - updatedXeris Pharmaceuticals (NSDQ:XERS) touted data this month for its ready-to-use glucagon auto-injector, highlighting the device’s efficacy and usability.

The Chicago-based company’s rescue pen is under review for approval by the FDA as a treatment for severe hypoglycemia in people with diabetes.

“Hypoglycemia can quickly evolve from a mild event to an emergency, so prompt and reliable intervention is critically important. Robust research supports our investigational ready-to-use liquid glucagon pen as an effective, user-friendly alternative to currently marketed products,” chairman & CEO Paul Edick said in prepared remarks. “On the heels of our recent regulatory filing, we are now actively working toward our goal of introducing this important innovation to the diabetes community.”

In one Phase III trial, researchers compared the Xeris glucagon pen to a commercially-available glucagon emergency kit (GEK) to treat severe hypoglycemia in 81 adults with Type 1 diabetes.

Xeris’ glucagon pen was able to more quickly resolve global symptoms of hypoglycemia, the company touted – 11.6 minutes compared to 13.1 minutes for the GEK.

In a separate usability study, 14 of 16 participants successfully administered a complete injection using Xeris’ glucagon pen compared to just 5 of 16 for the GEK. In a validation study among 75 adults, 98.7% of participants successfully used the glucagon pen.

Across all of the data presented at the 18th Annual Diabetes Technology meeting, Xeris noted that its device was safe and effective for those who were familiar and unfamiliar to using the pen.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: xerispharmaceuticals

IN CASE YOU MISSED IT

  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS